A PLACEBO-CONTROLLED, MULTICENTER, DOUBLE-BLIND, RANDOMISED TRIAL OF EMRICASAN IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND RAISED TRANSAMINASES

被引：19
|
作者：
Shiffman, M. [1 ]
Freilich, B. [2 ]
Vuppalanchi, R. [3 ]
Watt, K. [4 ]
Burgess, G. [5 ]
Morris, M. [5 ]
Sheedy, B. [5 ]
Schiff, E. [6 ]
机构：
[1] Bon Secours Hlth Syst Richmond & Newport News, Liver Inst Virginia, Richmond Newport News, VA USA
[2] Kansas City Res Inst, Kansas City, KS USA
[3] Indiana Univ Sch Med, Div Gastroenterol & Hepatol 3, Indianapolis, IN 46202 USA
[4] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[5] Conatus Pharmaceut Inc, San Diego, CA USA
[6] Univ Miami, Div Hepatol, Miami, FL USA
来源：
JOURNAL OF HEPATOLOGY | 2015年 / 62卷
关键词：
D O I：
10.1016/S0168-8278(15)30191-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LP37
引用
收藏
页码：S282 / S282
页数：1
相关论文
共 50 条
  • [31] Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial
    Song, Lihua
    Zhao, Xin Gang
    Ouyang, Peng Ling
    Guan, Qi
    Yang, Li
    Peng, Fengju
    Du, Huanwang
    Yin, Fei
    Yan, Wei
    Yu, Wen Juan
    Yan, Hongli
    BRITISH JOURNAL OF NUTRITION, 2020, 123 (10) : 1148 - 1158
  • [32] Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran
    Baniasadi, Nadieh
    Salajegheh, Faranak
    Pardakhty, Abbas
    Seyedmirzaee, Seyed Mehdi
    Hayatbakhsh, Mohammad Mahdi
    Nikpoor, Amin Reza
    Mohammadi, Mojgan
    HEPATITIS MONTHLY, 2015, 15 (11)
  • [33] A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a multispecies probiotic mixture in obese non-alcoholic fatty liver disease
    Ahn, S. B.
    Jun, D. W.
    Saeed, W. K.
    Lee, J. S.
    Chae, Y. J.
    Oh, H. W.
    Jeong, J. Y.
    Kang, H. T.
    Jang, E. C.
    Kang, B. -K.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S592 - S592
  • [34] Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease
    Shiffman, Mitchell
    Freilich, Bradley
    Vuppalanchi, Raj
    Watt, Kymberly
    Chan, Jean L.
    Spada, Al
    Hagerty, David T.
    Schiff, Eugene
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (01) : 64 - 73
  • [35] Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
    Loomba, Rohit
    Morgan, Erin
    Watts, Lynnetta
    Xia, Shuting
    Hannan, Lisa A.
    Geary, Richard S.
    Baker, Brenda F.
    Bhanot, Sanjay
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (09): : 829 - 838
  • [36] Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Chehrehgosha, Haleh
    Sohrabi, Masoud Reza
    Ismail-Beigi, Faramarz
    Malek, Mojtaba
    Babaei, Mohammad Reza
    Zamani, Farhad
    Ajdarkosh, Hossein
    Khoonsari, Mahmood
    Fallah, Afshin Eshghi
    Khamseh, Mohammad E.
    DIABETES THERAPY, 2021, 12 (03) : 843 - 861
  • [37] Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Haleh Chehrehgosha
    Masoud Reza Sohrabi
    Faramarz Ismail-Beigi
    Mojtaba Malek
    Mohammad Reza Babaei
    Farhad Zamani
    Hossein Ajdarkosh
    Mahmood Khoonsari
    Afshin Eshghi Fallah
    Mohammad E. Khamseh
    Diabetes Therapy, 2021, 12 : 843 - 861
  • [38] EFFECTS OF ORAL HIGH-DOSE VITAMIN D SUPPLEMENTATION ON NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Barchetta, I.
    Angelico, F.
    Del Ben, M.
    Di Martino, M.
    Fraioli, A.
    La Torre, G.
    Morini, S.
    Tiberti, C.
    Del Vescovo, R.
    Bertoccini, L.
    Cimini, F. A.
    Catalano, C.
    Baroni, M. G.
    Cavallo, M. G.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S483 - S483
  • [39] Green tea with high-density catechins improves liver function and fat infiltration in non-alcoholic fatty liver disease (NAFLD) patients: A double-blind placebo-controlled study
    Sakata, Ryuichiro
    Nakamura, Toru
    Torimura, Takuji
    Ueno, Takato
    Sata, Michio
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 (05) : 989 - 994
  • [40] RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL: LONG-TERM RESVERATROL TREATMENT FOR NON-ALCOHOLIC FATTY LIVER DISEASE
    Heeboll, S.
    Hamilton-Dutoit, S.
    Hellberg, Y. K.
    Stodkilde-Jorgensen, H.
    Jessen, N.
    Pedersen, S. B.
    Gronbaek, H.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S739 - S739
12345